文献速递血栓与止血

纤溶与COVID-19:纤溶酶 paradox

Fibrinolysis and COVID-19: A plasmin paradox.
PubMed 文献 · J Thromb Haemost · 2020-07-15

本文探讨COVID-19中D-二聚体显著升高与纤溶系统关系,指出D-二聚体升高可能反映纤溶系统清除纤维蛋白和坏死组织失败,增加纤溶活性可能对危重呼吸衰竭患者有益,但冠状病毒也可利用纤溶系统促进感染,抗纤溶措施似乎也合适,形成纤溶酶形成的临床paradox,关键在于时机。

要点

  • COVID-19中D-二聚体显著升高是预后不良标志,但不一定提示因果。
  • D-二聚体升高可能反映纤溶系统清除纤维蛋白和坏死组织失败。
  • 纤溶酶形成在COVID-19中可能有害也可能有益,取决于时机。

核心结论

  • 纤溶酶形成在COVID-19中可能有害也可能有益,关键在于时机。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • COVID-19中D-二聚体水平异常升高,是预后不良标志,但不一定提示因果。
  • D-二聚体显著升高可能反映纤溶系统清除肺实质纤维蛋白和坏死组织失败,在此过程中被消耗或 overwhelmed。
  • 近期研究提示增加纤溶活性可能为危重病和严重呼吸衰竭患者带来希望。
  • 冠状病毒也可利用纤溶系统促进感染性,抗纤溶措施似乎也合适。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The COVID-19 pandemic has provided many challenges in the field of thrombosis and hemostasis. Among these is a novel form of coagulopathy that includes exceptionally high levels of D-dimer. D-dimer is a marker of poor prognosis, but does this also imply a causal relationship? These spectacularly raised D-dimer levels may actually signify the failing attempt of the fibrinolytic system to remove fibrin and necrotic tissue from the lung parenchyma, being consumed or overwhelmed in the process. Indeed, recent studies suggest that increasing fibrinolytic activity might offer hope for patients with critical disease and severe respiratory failure. However, the fibrinolytic system can also be harnessed by coronavirus to promote infectivity and where antifibrinolytic measures would also seem appropriate. Hence, there is a clinical paradox where plasmin formation can be either deleterious or beneficial in COVID-19, but not at the same time. Hence, it all comes down to timing.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Medcalf RL, Keragala CB, Myles PS, et al. Fibrinolysis and COVID-19: A plasmin paradox. J Thromb Haemost. 2020. PMID: 32543119. doi:10.1111/jth.14960

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。